collection
MENU ▼
Read by QxMD icon Read
search

Lung

shared collection
7 papers 0 to 25 followers
By Saadvik Raghuram Mbbs graduate, persuing radiation oncology
https://www.readbyqxmd.com/read/27393514/advanced-non-small-cell-lung-cancer-patients-at-the-extremes-of-age-in-the-era-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors
#1
Yu-Mu Chen, Chien-Hao Lai, Kun-Ming Rau, Cheng-Hua Huang, Huang-Chih Chang, Tung-Ying Chao, Chia-Cheng Tseng, Wen-Feng Fang, Yung-Che Chen, Yu-Hsiu Chung, Yi-Hsi Wang, Mao-Chang Su, Kuo-Tung Huang, Shih-Feng Liu, Hung-Chen Chen, Ya-Chun Chang, Yu-Ping Chang, Chin-Chou Wang, Meng-Chih Lin
OBJECTIVES: The clinical characteristics and survival of very young (≤40 years) and very old (>80years) patients with advanced non-small cell lung cancer (NSCLC) are distinct. However, the benefits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to patients at the extremes of age with NSCLC harboring EGFR mutation have not been well studied. We retrospectively studied the effect of extreme age on patients' clinical characteristics and prognosis. MATERIALS AND METHODS: Of 1510 lung cancer patients diagnosed between November 2010 and March 2014, 555 patients who were tested for EGFR mutations were included...
August 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27223332/first-line-treatment-of-advanced-epidermal-growth-factor-receptor-egfr-mutation-positive-non-squamous-non-small-cell-lung-cancer
#2
REVIEW
Janette Greenhalgh, Kerry Dwan, Angela Boland, Victoria Bates, Fabio Vecchio, Yenal Dundar, Pooja Jain, John A Green
BACKGROUND: Epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell lung cancer (NSCLC) is emerging as an important subtype of lung cancer comprising 10% to 15% of non-squamous tumours. This subtype is more common in women than men and is less associated with smoking. OBJECTIVES: To assess the clinical effectiveness of single -agent or combination EGFR therapies used in the first-line treatment of people with locally advanced or metastatic EGFR M+ NSCLC compared with other cytotoxic chemotherapy (CTX) agents used alone or in combination, or best supportive care (BSC)...
May 25, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27189523/impact-of-heart-and-lung-dose-on-early-survival-in-patients-with-non-small-cell-lung-cancer-treated-with-chemoradiation
#3
Susan L Tucker, Anwen Liu, Daniel Gomez, Ling Long Tang, Pamela Allen, Jinzhong Yang, Zhongxing Liao, David Grosshans
BACKGROUND AND PURPOSE: To determine whether the impact of heart dose on early overall survival (OS) reported in RTOG 0617 could be confirmed in an independent cohort. MATERIALS AND METHODS: Heart and lung dose-volume histogram data were retrospectively extracted for patients with stage IIIA-IIIB non-small cell lung cancer (NSCLC) who had received radiotherapy using 3D CRT, IMRT or proton therapy delivered with concurrent chemotherapy between 1999 and 2010. Potential associations between clinical and dosimetric factors and OS up to 24months after start of treatment were assessed in univariate and multivariate analyses with log-rank tests or Cox proportional hazards models...
June 2016: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/27186518/erlotinib-plus-concurrent-whole-brain-radiation-therapy-for-non-small-cell-lung-cancers-patients-with-multiple-brain-metastases
#4
Danny Ulahannan, Siow-Ming Lee
Sequencing of the epidermal growth factor receptor (EGFR) gene to identify mutations in lung adenocarcinomas is routine in clinical practice. The use of tyrosine kinase inhibitors (TKIs) has transformed the management of patients with brain metastases harboring EGFR mutations, with improved response rates (RR) and survival. We evaluate the role of concurrent TKI therapy and radiotherapy in this group of patients, considering this data in the context of emerging concepts in this advancing field.
April 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27106020/targeted-therapy-combined-with-radiotherapy-in-non-small-cell-lung-cancer-a-review-of-the-oncologic-group-for-the-study-of-lung-cancer-spanish-radiation-oncology-society
#5
F Couñago, A Rodríguez, P Calvo, J Luna, J L Monroy, B Taboada, V Díaz, N Rodríguez de Dios
In recent years, major advances in our understanding of the molecular biology of lung cancer, together with significant improvements in radiotherapy technologies, have revolutionized the treatment of non-small cell lung cancer (NSCLC). This has led to the development of new therapies that target molecular mutations specific to each tumor type, acting on the cell surface antigens or intracellular signaling pathways, or directly affecting cell survival. At the same time, ablative dose radiotherapy can be delivered safely in the context of metastatic disease...
April 22, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27044418/quantification-of-the-smoking-associated-cancer-risk-with-rate-advancement-periods-meta-analysis-of-individual-participant-data-from-cohorts-of-the-chances-consortium
#6
José Manuel Ordóñez-Mena, Ben Schöttker, Ute Mons, Mazda Jenab, Heinz Freisling, Bas Bueno-de-Mesquita, Mark G O'Doherty, Angela Scott, Frank Kee, Bruno H Stricker, Albert Hofman, Catherine E de Keyser, Rikje Ruiter, Stefan Söderberg, Pekka Jousilahti, Kari Kuulasmaa, Neal D Freedman, Tom Wilsgaard, Lisette Cpgm de Groot, Ellen Kampman, Niclas Håkansson, Nicola Orsini, Alicja Wolk, Lena Maria Nilsson, Anne Tjønneland, Andrzej Pająk, Sofia Malyutina, Růžena Kubínová, Abdonas Tamosiunas, Martin Bobak, Michail Katsoulis, Philippos Orfanos, Paolo Boffetta, Antonia Trichopoulou, Hermann Brenner
BACKGROUND: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality...
April 5, 2016: BMC Medicine
https://www.readbyqxmd.com/read/26150526/egfr-inhibition-evokes-innate-drug-resistance-in-lung-cancer-cells-by-preventing-akt-activity-and-thus-inactivating-ets-1-function
#7
Janyaporn Phuchareon, Frank McCormick, David W Eisele, Osamu Tetsu
Nonsmall cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. About 14% of NSCLCs harbor mutations in epidermal growth factor receptor (EGFR). Despite remarkable progress in treatment with tyrosine kinase inhibitors (TKIs), only 5% of patients achieve tumor reduction >90%. The limited primary responses are attributed partly to drug resistance inherent in the tumor cells before therapy begins. Recent reports showed that activation of receptor tyrosine kinases (RTKs) is an important determinant of this innate drug resistance...
July 21, 2015: Proceedings of the National Academy of Sciences of the United States of America
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"